Development of a Novel Evaluation Scale of Mental Body Representation (MBR) for Adults With Spinal Cord Injury
Launched by UNIVERSITY OF MINNESOTA · Jun 11, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating and testing a new tool to better understand how adults with spinal cord injuries (SCI) perceive their own bodies. This includes how they are aware of their body and how they visualize it in space, which can sometimes change after an injury. The study aims to develop this new evaluation scale and see if it is easy to use, accurate, and reliable for people with SCI, including those who experience nerve-related pain.
Adults aged 18 and older with a spinal cord injury that happened at least a year ago may be eligible if they are medically stable, can read and understand English, and have access to the internet or a device like a phone or computer. There is also a control group of adults without SCI. Participants will take part in remote interviews or meetings via Zoom and will also visit the University of Minnesota for in-person testing with the new evaluation scale. They will be asked to complete questionnaires about their experience using the tool. People with certain medical conditions, such as uncontrolled seizures or severe cognitive impairments, may not be eligible. This study is currently recruiting participants and aims to improve how healthcare providers understand and assess body awareness in people with spinal cord injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Control group
- • Uninjured adults (from the contact list with the Brain Body Mind lab or through fliers or StudyFinder)
- • 18+ years old adults
- • SCI group
- • 18+ years old, participants with an incomplete or complete SCI of ≥ 1 year
- • medically stable
- • able to read and understand English
- • having access to the internet/iPad/computer/phone and willing to come in for an in-person testing at the University of Minnesota.
- Exclusion Criteria:
- • SCI group
- • Uncontrolled seizure disorder;
- • cognitive impairment and/or communicative disability (e.g., due to brain injury) preventing them from following directions or from learning;
- • ventilator dependency;
- • major medical complications;
- • pressure ulcers hindering prolonged sitting or lying down.
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Ann Van de Winckel
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported